Anxiety Disorders and Medical Cannabis

Types of Anxiety Disorders and Treatment Gaps

• Anxiety disorders include generalised anxiety disorder, social anxiety disorder, panic disorder and specific phobias; together they affect approximately one in five UK adults at some point in their lives.
• SSRI antidepressants and CBT are first-line treatments, but response rates are incomplete in around one third of patients and relapse on discontinuation is common.
• Benzodiazepines provide rapid relief but carry significant risks of dependence, tolerance and cognitive side effects, making long-term use clinically problematic.
• Patients who have failed multiple anxiety treatments and whose anxiety is secondary to a qualifying condition such as PTSD or chronic pain are most likely to qualify for medical cannabis.

The limitations of conventional anxiety pharmacotherapy have led increasing numbers of UK patients to investigate medical cannabis as a supplement or alternative to existing treatments.

How Cannabinoids Affect Anxiety

• CBD has been the most studied cannabinoid for anxiety; multiple preclinical and clinical studies show dose-dependent anxiolytic effects without the sedation or dependence risk of benzodiazepines.
• THC has a biphasic relationship with anxiety: low doses tend to reduce anxiety, while high doses can paradoxically increase it, particularly in inexperienced users.
• The endocannabinoid system regulates the hypothalamic-pituitary-adrenal (HPA) axis, which governs the stress response; cannabis modulation of this axis may reduce baseline anxiety.
• Terpenes including linalool, beta-caryophyllene and myrcene found in full-spectrum cannabis preparations may contribute additional anxiolytic and sedative effects.

The dose-dependency of THC’s anxiolytic versus anxiogenic effects underscores the importance of careful titration under specialist supervision for anxiety patients.

Clinical Evidence for Cannabis in Anxiety

• A 2019 prospective study of CBD treatment for anxiety and sleep in a clinical population showed a 79% reduction in anxiety scores at the first monthly assessment.
• UK clinical outcome data from the MCAP programme show significant improvements in GAD-7 (generalised anxiety) scores at 1, 3 and 6 months in patients prescribed cannabis for anxiety comorbidities.
• Observational data consistently shows that medical cannabis patients with anxiety reduce benzodiazepine use, with some eliminating it entirely under medical supervision.
• Limitations include a lack of large randomised controlled trials specifically in anxiety disorders; most evidence is observational or derived from PTSD populations.

The evidence base for cannabis in anxiety disorders is promising but not yet sufficient for NICE recommendation; UK specialist prescribers assess anxiety as an indication on a case-by-case basis.

Prescribing Considerations for Anxiety Patients

• Pure anxiety disorders without a comorbid qualifying condition may not qualify for a cannabis prescription in the UK; anxiety as a secondary condition alongside PTSD or chronic pain is more commonly accepted.
• Starting with a high-CBD, low-THC preparation is standard practice for anxiety patients; THC is titrated cautiously given its potential to worsen anxiety at higher doses.
• Daily journalling of anxiety symptoms between consultations gives the prescribing specialist the data needed to refine dose and product selection effectively.
• Concurrent talking therapy remains the recommended gold standard; cannabis should not be substituted for evidence-based psychological interventions.

UK anxiety patients considering medical cannabis should discuss their full treatment history with a specialist, including any previous adverse reactions to cannabinoids, before beginning a prescribing assessment.